Fuminori Moriyasu
Overview
Explore the profile of Fuminori Moriyasu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
259
Citations
4607
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nishimura T, Tada T, Akita T, Kondo R, Suzuki Y, Imajo K, et al.
J Gastroenterol
. 2025 Feb;
PMID: 39992415
Background: Attenuation Imaging (ATI) and controlled attenuation parameter (CAP) are non-invasive ultrasound-based methods for diagnosing hepatic steatosis. However, reports on the clinical usefulness of ATI are limited. We aimed to...
2.
Mine Y, Takada E, Sugimoto K, Moriyasu F
J Med Ultrason (2001)
. 2024 Sep;
51(4):691.
PMID: 39304553
No abstract available.
3.
Sugimoto K, Moriyasu F, Dioguardi Burgio M, Vilgrain V, Jesper D, Strobel D, et al.
Radiology
. 2024 Aug;
312(2):e233377.
PMID: 39162633
Background Attenuation coefficient (AC) and shear-wave speed (SWS) are established US markers for assessing patients with metabolic dysfunction-associated steatotic liver disease (MASLD), while shear-wave dispersion slope (DS) is not. Purpose...
4.
Mine Y, Takada E, Sugimoto K, Moriyasu F
J Med Ultrason (2001)
. 2024 May;
51(4):567-580.
PMID: 38780871
Sonazoid, an ultrasound contrast agent, has been covered by insurance in Japan since January 2007 for the diagnosis of hepatic mass lesions and is widely used for diagnosing not only...
5.
Sugimoto K, Lee D, Lee J, Yu S, Moriyasu F, Sakamaki K, et al.
Radiology
. 2021 Sep;
301(3):625-634.
PMID: 34519576
Background Nonalcoholic fatty liver disease (NAFLD) is common in the general population but identifying patients with high-risk nonalcoholic steatohepatitis (NASH) who are candidates for pharmacologic therapy remains a challenge. Purpose...
6.
Ferraioli G, Berzigotti A, Barr R, Choi B, Cui X, Dong Y, et al.
Ultrasound Med Biol
. 2021 Jul;
47(10):2803-2820.
PMID: 34284932
New ultrasound methods that can be used to quantitatively assess liver fat content have recently been developed. These quantitative ultrasound (QUS) methods are based on the analysis of radiofrequency echoes...
7.
Dietrich C, Nolsoe C, Barr R, Berzigotti A, Burns P, Cantisani V, et al.
Ultrasound Med Biol
. 2020 Jul;
46(10):2579-2604.
PMID: 32713788
The present, updated document describes the fourth iteration of recommendations for the hepatic use of contrast-enhanced ultrasound, first initiated in 2004 by the European Federation of Societies for Ultrasound in...
8.
Dietrich C, Nolsoe C, Barr R, Berzigotti A, Burns P, Cantisani V, et al.
Ultraschall Med
. 2020 Jul;
41(5):562-585.
PMID: 32707595
The present, updated document describes the fourth iteration of recommendations for the hepatic use of contrast enhanced ultrasound (CEUS), first initiated in 2004 by the European Federation of Societies for...
9.
Sugimoto K, Moriyasu F, Oshiro H, Takeuchi H, Abe M, Yoshimasu Y, et al.
Radiology
. 2020 Jun;
296(3):532-540.
PMID: 32573385
Background Nonalcoholic steatohepatitis (NASH) is diagnosed with histopathologic testing, but noninvasive surrogate markers are desirable for screening patients who are at high risk of NASH. Purpose To investigate the diagnostic...
10.
Sugimoto K, Moriyasu F, Oshiro H, Takeuchi H, Yoshimasu Y, Kasai Y, et al.
Ultrasonography
. 2019 Oct;
39(1):3-10.
PMID: 31645092
Shear wave (SW) dispersion imaging is a newly developed imaging technology for assessing the dispersion slope of SWs, which is related to tissue viscosity in diffuse liver disease. Our preclinical...